Pfizer receives EC approval for Hympavzi to treat haemophilia
The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or
Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of Alzheimer’s disease (AD), including the clinical progression of its lead candidate, GSM-779690T.